DE69332637D1 - Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers - Google Patents

Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers

Info

Publication number
DE69332637D1
DE69332637D1 DE69332637T DE69332637T DE69332637D1 DE 69332637 D1 DE69332637 D1 DE 69332637D1 DE 69332637 T DE69332637 T DE 69332637T DE 69332637 T DE69332637 T DE 69332637T DE 69332637 D1 DE69332637 D1 DE 69332637D1
Authority
DE
Germany
Prior art keywords
cell line
monoclonal antibody
producing
hybridoma cell
protein conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332637T
Other languages
English (en)
Other versions
DE69332637T2 (de
Inventor
Keiko Yugawa
Nobuyuki Sigetoh
Jinsei Miyazaki
Tadayasu Mitsumata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Panasonic Holdings Corp
Original Assignee
Matsushita Electric Industrial Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP4350293A external-priority patent/JPH06256345A/ja
Priority claimed from JP5053380A external-priority patent/JPH06261782A/ja
Application filed by Matsushita Electric Industrial Co Ltd filed Critical Matsushita Electric Industrial Co Ltd
Application granted granted Critical
Publication of DE69332637D1 publication Critical patent/DE69332637D1/de
Publication of DE69332637T2 publication Critical patent/DE69332637T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/946—CNS-stimulants, e.g. cocaine, amphetamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69332637T 1993-03-04 1993-07-16 Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers Expired - Fee Related DE69332637T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4350293A JPH06256345A (ja) 1993-03-04 1993-03-04 コカイン誘導体およびそのタンパク質コンジュゲート
JP5053380A JPH06261782A (ja) 1993-03-15 1993-03-15 モノクローナル抗体産生細胞ライン作製方法、モノクローナル抗体産生細胞ラインおよびモノクローナル抗体

Publications (2)

Publication Number Publication Date
DE69332637D1 true DE69332637D1 (de) 2003-02-20
DE69332637T2 DE69332637T2 (de) 2003-10-23

Family

ID=26383284

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332637T Expired - Fee Related DE69332637T2 (de) 1993-03-04 1993-07-16 Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers

Country Status (3)

Country Link
US (2) US6174723B1 (de)
EP (1) EP0613899B1 (de)
DE (1) DE69332637T2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5623588A (en) * 1992-12-14 1997-04-22 New York University Computer user interface with non-salience deemphasis
US5840307A (en) * 1995-03-31 1998-11-24 Immulogic Pharmacuetical Corp. Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation
ES2210356T3 (es) * 1995-03-31 2004-07-01 Xenova Research Limited Conjugados de haptano-transportador para empleo en terapia contra el uso de drogas.
US20020102659A1 (en) * 1997-03-21 2002-08-01 Jean-Michel Scherrmann Cocaethylene immunogens and antibodies
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
DE10326821A1 (de) * 2003-06-11 2005-01-05 Medical Enzymes Ag Pharmazeutische Kombinationspräparate zur Krebstherapie
US7105643B2 (en) * 2003-07-30 2006-09-12 The United States Of America As Represented By The Attorney General Of The Dept. Of Justice Monoclonal antibodies specific for crack cocaine metabolites, a cell line producing the same, and crack cocaine conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045420A (en) * 1973-05-29 1977-08-30 Syva Company Non-oxo-carbonyl containing benzoyl ecgonine and cocaine compounds polypeptide and derivatives thereof
US3888866A (en) * 1973-06-01 1975-06-10 Syva Co Nitrogen derivatives of benzoyl ecgonine
JPH04182499A (ja) * 1990-11-14 1992-06-30 Matsushita Electric Ind Co Ltd エクゴニン・タンパク質コンジュゲート及びその誘導体
US5233042A (en) * 1991-12-16 1993-08-03 Biosite Diagnostics, Inc. Cocaine derivatives
US5808074A (en) * 1996-02-02 1998-09-15 Georgetown University Benzoylecgonine conjugate diagnostic reagents

Also Published As

Publication number Publication date
US6174723B1 (en) 2001-01-16
DE69332637T2 (de) 2003-10-23
US6271381B1 (en) 2001-08-07
EP0613899A2 (de) 1994-09-07
EP0613899A3 (de) 1995-01-18
EP0613899B1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
DE122004000017I1 (de) Monoklonaler Antik¦rper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren f}r die Herstellung des gereinigten Cytotoxin.
DE69528991D1 (de) Modifiziertes molke-protein und ein verfahren für seine herstellung
CA2103059A1 (en) Method for making humanized antibodies
DE69410470D1 (de) Modifiziertes konjugiertes diencopolymer, verfahren zu dessen herstellung und zusammensetzung daraus
DE69526315D1 (de) Wärmeisolierender Behälter und Verfahren zu dessen Herstellung
ZA9510806B (en) Anti-xv-integrin monoclonal antibody
DE69420493D1 (de) Diamantartiges, kohlenstoffhaltiges material und verfahren zu seiner erzeugung
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
DE69633610D1 (de) Flüssigkeitabsorbierendes material und verfahren zu dessen herstellung
EP0761683A4 (de) Protein oder polypeptid, verfahren zur seiner herstellung und entsprechende zwischenprodukte
EP0741144A4 (de) Monoklonaler antikörper gegen antiannexin-v, verfahren zu seiner herstellung und seiner verwendung
AU7198291A (en) Human monoclonal antibodies against rabies viruses, the production and the use thereof
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
AU2712192A (en) Monoclonal antibodies against mycoplasma pneumoniae, hybridomas producing these, methods for the preparation thereof, and the use thereof
DE69332637D1 (de) Kokainderivat,Proteinkonjugat,davon,einen monoklonalen Antikörper produzierende Hybridom-Zellinie, Verfahren zur Herstellung der Hybridom-Zellinie und des monoklonalen Antikörpers
AU8866791A (en) Monoclonal antibody for use in diagnosing alzheimer&#39;s disease, hybridoma secreting said antibody and preparation method therefor
DE69527088D1 (de) Tierkotbehandlungsmaterial und verfahren zu dessen herstellung
EP0759943A4 (de) Monoklonale antikörper spezifisch gegen vaskuläres endothelzellartigen endoglyx-1, das antigen selbst und seine verwendungen
AU5809290A (en) Monoclonal antibodies involved in alzheimer&#39;s disease, hybridomas secreting these monoclonal antibodies, antigen recognized by these antibodies, and their application
ATE123785T1 (de) Verfahren zur herstellung vo propylen-ethylen- copolymerisaten.
DE3574601D1 (de) Antitetanus-antikoerper herstellender human-human-hybridoma und verfahren zu seiner herstellung.
DE69609176D1 (de) Bindemittelharz, verfahren zu seiner herstellung und zusammensetzungen damit
AU7504691A (en) Monoclonal antibodies against pp4, processes for the preapration thereof and the use thereof
DE69014169D1 (de) Polstermaterial und Verfahren für dessen Herstellung.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee